Charles River Laboratories’s ( CRL) share price has entered into oversold territory with an RSI value of 29.8. The Zacks Consensus Estimate for Charles River Laboratories for the full year period has improved 9 cents over the past two months to $3.16 per share. Currently, Charles River Laboratories has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on ( CRL) after its recent drop.
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment